+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 19 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.

Age: 18Years +All GendersPhase 3
325 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
I

Actively Recruiting

Researchers are investigating autoinflammatory diseases AID, which involve recurring inflammatory episodes without infection, cancer, or adaptive immune system problems. This study focuses on both monogenic hereditary periodic syndromes and polygenic or multifactorial AID, including rare conditions like Behets disease, Still disease, Schnitzlers disease, PFAPA syndrome, chronic recurrent multifocal osteomyelitis, non-infectious uveitis and scleritis, among others. The goal is to gather detailed data to improve understanding and management of these rare diseases through an international collaboration. The study uses the AIDA registry, a secure online platform for collecting demographic, genetic, clinical, laboratory, radiologic, and therapeutic information. Data are gathered retrospectively and prospectively during routine clinical visits scheduled every 3-6 months. Eleven registries focus on different AID conditions, enabling comprehensive data collection to identify clinical patterns, treatment impacts, and long-term outcomes over a period of at least 10 years. Participants provide information during their usual care visits, allowing researchers to track changes in disease activity, organ involvement, inflammatory markers, visual function, pain levels, fatigue, fertility, and socioeconomic factors. The study monitors these outcomes over multiple timepoints up to 120 months. Data privacy is ensured by pseudonymizing patient information. This registry supports multiple clinical studies and aims to enhance knowledge, awareness, and future research on autoinflammatory diseases worldwide.

All AgesAll Genders
112 locations
M

Actively Recruiting

Researchers are studying women who carry mutations in the breast cancer susceptibility genes BRCA1 and BRCA2 to better understand their risk of developing cancer. This observational study aims to collect national data from women with these mutations, as current management strategies are not fully established. The study focuses on the Italian population, where an estimated 140,000 to 150,000 women carry these mutations, and many face a high lifetime risk of genetically linked tumors. Participants will be registered on a platform where their clinical data related to BRCA1 or BRCA2 mutations will be collected. The study does not involve treatment but gathers detailed information about mutation distribution, access to genetic evaluation, lifestyle risk factors, preventive strategies, and surgical risk reduction approaches such as salpingo-oophorectomy. Women in the study will provide data that researchers will analyze to understand mutation geography, related cancer types, and screening criteria. Data collection occurs over different time frames, including immediate and six-month intervals. The study continues through long-term observation to monitor outcomes and preventive efforts, with no active intervention applied to participants.

Age: 18Years +FEMALE
40 locations
T

Actively Recruiting

Researchers are investigating the order in which early symptoms, called premonitory symptoms, appear before migraine headaches. These symptoms mark the start of a migraine attack and involve changes in brain activity. However, the exact sequence of these symptoms and brain changes remains unclear, and this study aims to fill that gap by tracking these symptoms across multiple migraine episodes. Participants will use a special electronic diary to record the type, order, start time, and duration of premonitory symptoms during up to five migraine attacks. They will be asked to make these entries as soon as possible at headache onset, with timestamps to reduce memory errors. Data collection uses a structured diary on the REDCap platform and a standardized case report form. During the study, participants will track their symptoms across several migraine attacks over up to six months. Researchers will assess how often each symptom appears first, the timing between symptoms and headache, and the consistency of symptoms across attacks. They will also compare reported symptoms with diary data, evaluate symptom impact on disability, and monitor symptom evolution during headache phases.

Age: 18Years - 65YearsAll Genders
1 location
C

Actively Recruiting

This trial studies patients with early stage Follicular Lymphoma who have not received prior treatment. It is a phase III, multicenter, randomized clinical trial comparing two treatments to evaluate which approach better controls the disease. The study is open label, meaning both patients and researchers know the assigned treatments. The purpose is to assess progression-free survival and other outcomes over several years. Participants are randomly assigned to one of two groups one receives involved-site radiotherapy alone at a standard dose of 24 Gy, and the other receives the same radiotherapy followed by eight doses of Obinutuzumab given intravenously over approximately nine months. The Obinutuzumab doses start with four weekly infusions followed by four infusions every three weeks. This comparison aims to evaluate the potential benefit of adding Obinutuzumab to radiotherapy. During the study, participants undergo PETCT scans for staging and assessments, blood tests including PCR for molecular markers, bone marrow biopsies, and other laboratory tests to monitor response and safety. Researchers measure outcomes such as progression-free survival over 33 months, complete and overall response rates, and event-free survival over up to 45 months. Safety and molecular studies including liquid biopsies and genetic analyses are also performed. Participants are followed for several years to monitor disease status and side effects.

Age: 18Years +All GendersPhase 3
49 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of rimegepant compared to a placebo as a preventative treatment for children and adolescents aged 6 to under 18 years with episodic migraine. The study focuses on reducing the number of migraine days per month and improving quality of life in this young population. It is a Phase 3, randomized, double-blind, placebo-controlled trial sponsored by Pfizer. Participants receive either rimegepant in doses of 75mg or 50mg two 25mg orally disintegrating tablets or a matching placebo with the same dosing options. The study uses a double-blind design over a 12-week treatment phase to compare outcomes. The research also monitors safety and tolerability for up to 72 weeks, including the frequency of liver-related adverse events. During the study, participants will have assessments to record migraine days and severity, use of acute migraine medications, and quality of life using the Pediatric Quality of Life Inventory. Researchers will track safety through ongoing monitoring for adverse effects. The primary measure is the change in mean monthly migraine days over 12 weeks, with additional evaluations during the first 4 weeks and longer-term safety follow-up. Total participation may last up to 72 weeks for safety evaluation.

Age: 6Years - 17YearsAll GendersPhase 3
93 locations
P

Actively Recruiting

The trial investigates treatment options for adults aged 18 to 70 with newly diagnosed higher-risk myelodysplastic syndromes HR-MDS, focusing on the feasibility of allogeneic stem cell transplantation HSCT. It compares upfront HSCT with pre-treatment using azacitidine or conventional chemotherapy based on the patients bone marrow blast counts. This phase III, open-label, randomized multicenter study aims to determine whether pre-transplant treatments affect the ability to proceed with HSCT. Participants are assigned to groups depending on their bone marrow blast levels. Those with 10% or more blasts receive either conventional chemotherapy following a 37 protocol or azacitidine given subcutaneously at 75 mgm2 daily for 7 days every 28 days for at least 4 cycles before HSCT if a suitable donor is available. Patients with less than 10% blasts may receive upfront HSCT or azacitidine prior to HSCT under similar dosing schedules. The study evaluates these different sequences of therapy to assess HSCT feasibility. During the study, participants undergo regular assessments over four years to monitor whether they proceed to HSCT. Researchers track treatment outcomes, safety, and overall feasibility by measuring the proportion of randomized patients who receive the transplantation. The trial includes follow-up for at least four years to collect data on these outcomes and ensure participant safety and treatment adherence throughout the process.

Age: 18Years - 70YearsAll GendersPhase 3
46 locations
P

Actively Recruiting

Researchers are evaluating the effect of adding gemtuzumab ozogamicin to standard chemotherapy for adults aged 18 to 60 with newly diagnosed favorable or intermediate-risk acute myeloid leukemia AML. This phase 3 study aims to reduce minimal residual disease MRD levels before transplantation and assess whether MRD-driven post-remission therapy can improve anti-leukemic outcomes. The study excludes patients with certain genetic markers or prior treatments to focus on a specific AML subgroup. Participants receive induction treatment with gemtuzumab, daunorubicin, and cytosine arabinoside, followed by consolidation therapy with adjusted doses of these drugs. After consolidation, patients undergo either autologous or allogeneic stem cell transplantation based on their MRD level. This MRD-guided approach helps tailor the intensity of post-remission therapy. Throughout the study, participants undergo MRD assessments to measure treatment activity, with the primary outcome being MRD negativity two months after starting therapy. Researchers also monitor kidney and liver function, heart health, and overall compliance with study procedures. The study involves regular clinical observations and assessments to evaluate the effectiveness of the combined treatment and its impact on MRD levels over time.

Age: 18Years - 60YearsAll GendersPhase 3
48 locations
S

Actively Recruiting

Researchers are evaluating the effect of inhibiting late INa current with ranolazine to improve coronary microcirculation in patients who have acute myocardial infarction heart attack with multivessel disease. This Phase IIb open-label study aims to compare ranolazine plus standard therapy against standard therapy alone in preserving coronary microcirculation after successful primary percutaneous coronary intervention pPCI. The study also investigates various secondary outcomes such as coronary microvascular dysfunction CMD, infarct size, endothelial function, major cardiovascular events, angina symptoms, and quality of life. Participants will be randomly assigned to one of two groups the experimental group will receive oral ranolazine starting at 500 mg twice daily, increased to 750 mg twice daily from 7 days after pPCI to up to 6 weeks the control group will receive standard therapy without ranolazine. Coronary microcirculation will be assessed invasively or by angiography-based Index of Microcirculatory Resistance IMRangioIMR at baseline after pPCI and at follow-up during staged PCI of non-culprit lesions, either within 5 days or up to 6 weeks. The study is conducted at multiple centers and follows patients for up to 8 weeks. Participants will undergo coronary microcirculation measurements at two time points along with cardiac magnetic resonance imaging to assess infarct size. Additional assessments include evaluations of endothelial function using EndoPAT, angina symptoms through SAQ7, and quality of life using EuroQoL questionnaires. The study monitors major adverse cardiovascular events MACE, periprocedural myocardial infarction, and other clinical outcomes. The total participation duration lasts approximately 6 to 8 weeks after initial pPCI with close clinical follow-up during this period.

Age: 18Years - 80YearsAll GendersPhase 2Phase 3
3 locations

1-10 of 19

1